CMO Noah Rosenberg to step down Dec 31, 2021; to serve as executive advisor through 2022
Travere Therapeutics, Inc.
Noah Rosenberg will transition from CMO to executive advisor effective Dec 31, 2021.
He will continue as CMO until year-end, then advise through 2022 on clinical trial oversight and regulatory submissions.
Transition agreement provides severance benefits consistent with existing employment agreement.
Post-transition consulting includes monthly retainer through May 2022, hourly fees June-Dec 2022, and success bonus tied to FDA acceptance of sparsentan NDA.
Stock awards continue vesting; severance amendments extend certain benefits to 18 months.
On October 12, 2021, Travere Therapeutics, Inc. (the “Company”) announced that its chief medical officer, Noah Rosenberg, M.D., will be transitioning to an executive advisor role at the end of 2021.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Noah Rosenberg changed role as executive advisor at Travere Therapeutics, Inc..
Action
transitioning
Role
executive advisor
Exact text from the filing
On October 12, 2021, Travere Therapeutics, Inc. (the “Company”) announced that its chief medical officer, Noah Rosenberg, M.D., will be transitioning to an executive advisor role at the end of 2021.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.